Interpretation of Incidence Rates Data
Incidence Rate Report for District of Columbia
Explanation of Column Headers
Non-Hodgkin Lymphoma (Late Stage^), 2016-2020
All Races (includes Hispanic), Both Sexes, All Ages
Sorted by Percentlate
Percent of Cases with Late Stage - This is the number of late stages cases compared to the number of cases for all stages.
- Larger confidence intervals indicate less stability of the data. This is often due to low counts that are not quite low enough to be suppressed.
- Data is currently being suppressed if there are fewer than 16 counts for the time period.
Line by Line Interpretation of the Report
District of Columbia6
- Rate : The incidence rate is 9.0 with a 95% confidence interval from 8.0 to 10.1 and 62 average annual cases over 2016-2020.
- CI*Rank⋔ : 48 (40, 49)
- Percent of Cases with Late Stage : 61.8
- Rate : The incidence rate is 12.0 with a 95% confidence interval from 11.9 to 12.0 and 45,317 average annual cases over 2016-2020.
- CI*Rank⋔ : N/A
- Percent of Cases with Late Stage : 64.4
Created by statecancerprofiles.cancer.gov on 09/26/2023 1:10 pm.
State Cancer Registries may provide more current or more local data.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.
† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.
Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.
^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).
Interpret Rankings provides insight into interpreting cancer incidence statistics. When the population size for a denominator is small, the rates may be unstable. A rate is unstable when a small change in the numerator (e.g., only one or two additional cases) has a dramatic effect on the calculated rate.
Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
When displaying county information, the CI*Rank for the state is not shown because it's not comparable. To see the state CI*Rank please view the statistics at the US By State level.